Literature DB >> 10561095

Surgical strategy for the treatment of medullary thyroid carcinoma.

J B Fleming1, J E Lee, M Bouvet, P N Schultz, S I Sherman, R V Sellin, K E Friend, M A Burgess, G J Cote, R F Gagel, D B Evans.   

Abstract

OBJECTIVE: To evaluate surgical complications, patterns of lymph node metastases, and calcitonin response to compartment-oriented lymphadenectomy in patients with primary or recurrent medullary thyroid carcinoma (MTC). SUMMARY BACKGROUND DATA: The majority of patients with invasive MTC have metastasis to regional lymph nodes at the time of diagnosis, as evidenced by the frequent finding of persistently elevated calcitonin levels after thyroidectomy and the high rates of recurrence in the cervical lymph nodes reported in retrospective studies. These data have provided the rationale for surgeons to perform a more extensive lymphadenectomy at the time of initial thyroidectomy and to consider reoperative cervical lymphadenectomy in patients with persistently elevated calcitonin levels after thyroidectomy.
METHODS: Forty patients underwent surgery for MTC from 1991 to 1997 (23 sporadic cases, 17 familial cases). Patients were divided into three groups based on whether they had undergone previous thyroidectomy and on the results of standardized staging studies performed after referral to the authors' institution. Group 1 (11 patients) had received no previous surgery; group 2 (13) underwent thyroidectomy before referral and had an elevated calcitonin level without radiologic evidence of local regional or distant metastases; and group 3 (16) underwent thyroidectomy before referral and had an elevated calcitonin level with radiologic evidence of local-regional recurrence. The central neck compartment was dissected in all patients; preoperative staging and the extent of previous surgery dictated the need for lateral (modified radical) neck dissection. After primary or reoperative surgery, calcitonin levels were assessed.
RESULTS: All patients had major reductions in postoperative calcitonin levels. Seven (29%) of 24 patients in groups 1 and 2 achieved normal calcitonin values compared with only 1 (6%) of 16 in group 3. Postoperative complications included seven cases (17%) of permanent hypoparathyroidism; five (71%) of these occurred in group 3. There were no iatrogenic recurrent laryngeal nerve injuries; one patient required recurrent nerve resection to achieve complete tumor extirpation. At a median follow up of 35 months, local recurrence was documented in 5 (13%) of 40 patients.
CONCLUSIONS: Compartment-oriented lymphadenectomy performed early in the course of MTC is safe and may return calcitonin levels to normal in up to 25% of carefully selected patients. However, reoperation for bulky cervical disease (group 3) rarely results in normal calcitonin levels and is associated with a high incidence of permanent hypoparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561095      PMCID: PMC1420925          DOI: 10.1097/00000658-199911000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  23 in total

1.  Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970.

Authors:  H Gharib; W M McConahey; R D Tiegs; E J Bergstralh; J R Goellner; C S Grant; J A van Heerden; G W Sizemore; I D Hay
Journal:  Mayo Clin Proc       Date:  1992-10       Impact factor: 7.616

2.  Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy.

Authors:  N A Samaan; P N Schultz; R C Hickey
Journal:  J Clin Endocrinol Metab       Date:  1988-10       Impact factor: 5.958

3.  Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content.

Authors:  S Schröder; W Böcker; H Baisch; C G Bürk; H Arps; I Meiners; H Kastendieck; P U Heitz; G Klöppel
Journal:  Cancer       Date:  1988-02-15       Impact factor: 6.860

4.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

5.  Management of medullary carcinoma of the thyroid.

Authors:  W J Simpson; J A Palmer; I B Rosen; R A Mustard
Journal:  Am J Surg       Date:  1982-10       Impact factor: 2.565

6.  Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization.

Authors:  K Frank-Raue; F Raue; H J Buhr; G Baldauf; D Lorenz; R Ziegler
Journal:  Thyroid       Date:  1992       Impact factor: 6.568

7.  Medullary carcinoma of the thyroid--therapeutic strategy derived from fifteen years of experience.

Authors:  F Kallinowski; H J Buhr; H Meybier; M Eberhardt; C Herfarth
Journal:  Surgery       Date:  1993-09       Impact factor: 3.982

8.  Localization and resection of clinically inapparent medullary carcinoma of the thyroid.

Authors:  J A Norton; J L Doppman; M F Brennan
Journal:  Surgery       Date:  1980-06       Impact factor: 3.982

9.  Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma.

Authors:  L E Tisell; G Hansson; S Jansson; H Salander
Journal:  Surgery       Date:  1986-01       Impact factor: 3.982

10.  Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma.

Authors:  N Abdelmoumene; M Schlumberger; P Gardet; A Roche; J P Travagli; C Francese; C Parmentier
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more
  19 in total

Review 1.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

2.  Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.

Authors:  G Papi; S M Corsello; K Cioni; A M Pizzini; S Corrado; C Carapezzi; G Fadda; A Baldini; C Carani; A Pontecorvi; E Roti
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature.

Authors:  E Prokopakis; M Doulaptsi; A Kaprana; S Velegrakis; Y Vlastos; G Velegrakis
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

4.  Alternative surgical strategies in patients with sporadic medullary thyroid carcinoma: Long-term follow-up.

Authors:  Shi Hong Ma; Qin Jiang Liu; You Cheng Zhang; Rong Yang
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

5.  Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

Authors:  D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 6.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

Review 8.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

9.  Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?

Authors:  Per Bümming; Håkan Ahlman; Bengt Nilsson; Ola Nilsson; Bo Wängberg; Svante Jansson
Journal:  Langenbecks Arch Surg       Date:  2008-07-15       Impact factor: 3.445

10.  Routine preoperative (111)In-octreotide scintigraphy in patients with medullary thyroid cancer.

Authors:  Jakob Dahlberg; Per Bümming; Peter Gjertsson; Svante Jansson
Journal:  Langenbecks Arch Surg       Date:  2013-05-19       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.